Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

Two types of androgen deprivation therapy (ADT) had different effects on coronary atherosclerosis in a small randomized trial of men with prostate cancer. Significantly more coronary artery plaque ...

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

This medication is a beneficial addition to your prostate cancer treatment plan — but it doesn’t come without risks. Here’s how to stay ahead of potential side effects. If you’ve been diagnosed with ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

If you’ve been diagnosed with advanced prostate cancer, there’s a good chance you’ll receive androgen deprivation therapy (ADT) at some point, as ADT is a mainstay of prostate cancer treatment. It ...